| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/25/2000 | US6017948 A pharmaceutically-acceptable anticancer drug paclitaxel in non-aqueous solvent comprising n-methyl pyrrolidone, excluding dimethylacetamide or dimethyl sulfoxide |
| 01/25/2000 | US6017943 Intramolecularly crosslinking hemoglobin to form a synthetic blood |
| 01/25/2000 | US6017920 Antifungal composition for external use being retentive in stratum corneum |
| 01/25/2000 | US6017901 Heavy metal salts of succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters, a process for their preparation and relative pharmaceutical compositions |
| 01/25/2000 | US6017900 Topical composition containing hyaluronic acid and nsaids |
| 01/25/2000 | US6017899 Non-reducing saccharide-forming enzyme, its preparation and uses |
| 01/25/2000 | US6017896 Purine nucleoside phosphorylase gene therapy for human malignancy |
| 01/25/2000 | US6017876 Monosuccinylated exclusively a n-terminus |
| 01/25/2000 | US6017567 Applying a sorbitol syrup to a rotating mass of cores, adding a polyol in a crystalline form comprising at least one member selected from the group consisting of xylitol, erythritol, and isomalt, drying, layering |
| 01/25/2000 | US6017560 Process for producing stabilized pharmaceutical composition |
| 01/25/2000 | US6017554 Composition for treating abnormal conditions of the epithelium of bodily orifices |
| 01/25/2000 | US6017549 Non-irritating cosmetic and pharmaceutical compositions |
| 01/25/2000 | US6017531 An extracellular neutral protease and a stabilizer of glyceryl cocoate as a wound healing agent and for debriding necrotic tissue; storage stable enzyme activity at room temperature; burns; cutaneous ulcers; pressure necroses incisional, |
| 01/25/2000 | US6017522 Segmented chelating polymers as imaging and therapeutic agents |
| 01/25/2000 | US6017521 Topically applying a composition comprising water and a water-swellable, water-insoluble, crosslinked, ph buffering, bioadhesive, carboxy-containing addition polymer to acidify; microbiocides; deodorizing |
| 01/25/2000 | US6017520 Penetration enhancement of topically applied therapeutic formulations |
| 01/25/2000 | US6017514 Contacting a labeled antibody specific to an internal cell component but not with external ones with tissue of a mammal that has received therapy to kill malignant cells; measuring the binding where the internal component is an antigen |
| 01/25/2000 | US6016862 Sand core |
| 01/25/2000 | CA2205546C Oral compositions containing ondansetron |
| 01/25/2000 | CA2107301C Muco adhesive polymers |
| 01/25/2000 | CA2073055C Nicotine containing stimulant unit |
| 01/20/2000 | WO2000002999A2 Medium and matrix for long-term proliferation of cells |
| 01/20/2000 | WO2000002950A1 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
| 01/20/2000 | WO2000002917A2 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | WO2000002601A2 Transdermal delivery system |
| 01/20/2000 | WO2000002600A1 Method of obscuring immune recognition |
| 01/20/2000 | WO2000002590A1 Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| 01/20/2000 | WO2000002588A1 Targeted site specific drug delivery compositions and method of use |
| 01/20/2000 | WO2000002587A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/20/2000 | WO2000002586A1 Pharmaceutical levothyroxine preparation |
| 01/20/2000 | WO2000002584A2 Cancer treatment methods using antibodies to aminophospholipids |
| 01/20/2000 | WO2000002582A2 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | WO2000002576A2 Egf-genistein for prevention of restenosis |
| 01/20/2000 | WO2000002574A1 Powdery preparation for mucosal administration containing polymeric medicine |
| 01/20/2000 | WO2000002568A1 Coumarin and related aromatic-based polymeric prodrugs |
| 01/20/2000 | WO2000002563A1 Steroid-containing cataplasms and process for producing the same |
| 01/20/2000 | WO2000002560A1 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE ORAL COMPOSITIONS |
| 01/20/2000 | WO2000002541A1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 01/20/2000 | WO2000002540A1 Plaster which contains steroids, and a method for the production and use thereof |
| 01/20/2000 | WO2000002539A1 Topical plaster with non-steroidal antirheumatic agents with an acid group |
| 01/20/2000 | WO2000002537A1 Composition containing glycerol trinitrate, method for producing said composition and use of the same |
| 01/20/2000 | WO2000002535A1 Improved stable topical ascorbic acid compositions |
| 01/20/2000 | WO2000002530A1 Saline and mineralized aqueous solution, and its use in cosmetics and dermopharmaceutics |
| 01/20/2000 | WO1999059633A8 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 01/20/2000 | WO1999059541A3 Cyclosporin preparations |
| 01/20/2000 | WO1999044604A9 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| 01/20/2000 | WO1999042091A3 Use of polycations as endosomolytic agents |
| 01/20/2000 | WO1999038472A3 Topical vasodilatory gel composition and methods of use and production |
| 01/20/2000 | WO1998042376A9 Composition comprising immunoglobulin |
| 01/20/2000 | WO1998027107A8 Method of coupling polysaccharides to proteins |
| 01/20/2000 | DE19831869A1 Use of pigments based on lamellar substrate for coloring food and pharmaceutical products |
| 01/20/2000 | CA2377178A1 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2]pyridine oral compositions |
| 01/20/2000 | CA2337680A1 Polyester analogue of poly-l-lysine as a soluble, biodegradable gene delivery carrier |
| 01/20/2000 | CA2336748A1 Pharmaceutical preparation |
| 01/20/2000 | CA2336704A1 Composition containing glycerol trinitrate, method for producing said composition and use of the same |
| 01/20/2000 | CA2333928A1 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | CA2333923A1 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | CA2331789A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/19/2000 | EP0972831A1 Antisense oligonucleotides against the alpha regulatory subunit of the cAMP dependent-protein kinase for treatment of cancer |
| 01/19/2000 | EP0972779A2 Oligonucleotide-polyamide conjugates |
| 01/19/2000 | EP0972528A2 Radioimmunoconjugate for use in human therapy and its preparation |
| 01/19/2000 | EP0972520A1 Freeze-dried composition of bone morphogenetic protein human mp52 |
| 01/19/2000 | EP0972511A1 Association of a retinoid with a histidine derivative |
| 01/19/2000 | EP0972063A2 Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
| 01/19/2000 | EP0971972A1 Polymers with thiol terminal function |
| 01/19/2000 | EP0971747A2 Contrast agents |
| 01/19/2000 | EP0971746A1 Solvent system for enhanced penetration of pharmaceutical compounds |
| 01/19/2000 | EP0971745A2 Gel delivery vehicles for anticellular proliferative agents |
| 01/19/2000 | EP0971743A1 Stabilized medicaments containing cysteinyl derivatives |
| 01/19/2000 | EP0971742A1 Obesity protein formulations |
| 01/19/2000 | EP0971729A1 Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| 01/19/2000 | EP0971705A1 Hormone replacement therapy drug formulations for topical application to the skin |
| 01/19/2000 | EP0971704A1 Comestible capsules having flavoured coatings |
| 01/19/2000 | EP0971703A1 Use of microparticles having a protein and an antibody adsorbed thereon for preparing a pharmaceutical composition for intranasal administration |
| 01/19/2000 | EP0971702A1 Microgranules containing cisplatin |
| 01/19/2000 | EP0971701A1 Method for removing high boiling solvents from drug formulations by vacuum drying |
| 01/19/2000 | EP0971699A1 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| 01/19/2000 | EP0971698A1 Aerosolized hydrophobic drug |
| 01/19/2000 | EP0971697A2 Medicament having sclerosing activity |
| 01/19/2000 | EP0971696A1 Thimerosal-free preservatives for vaccines |
| 01/19/2000 | EP0971694A1 Drug preparations for treating sexual dysfunction |
| 01/19/2000 | EP0971692A2 Specific magnetosome, method for the production and use thereof |
| 01/19/2000 | EP0971662A1 Fatty acid esters of glycolic acid and its salts as permeation enhancers |
| 01/19/2000 | EP0971641A1 Intravesical drug delivery system |
| 01/19/2000 | EP0897392A4 Isolation and use of sh3 binding peptides |
| 01/19/2000 | EP0859751B1 Semi-fluorinated alkanes and their use |
| 01/19/2000 | EP0847240A4 Novel embolizing compositions |
| 01/19/2000 | EP0843560A4 Cellulose diacetate compositions for use in embolizing blood vessels |
| 01/19/2000 | EP0809623B1 Alk(en)yl dicarboxylic acid bisesters, their use and method for preparing them |
| 01/19/2000 | EP0713395A4 Polymeric carriers for non-covalent drug conjugation |
| 01/19/2000 | EP0664713B1 Therapeutic and diagnostic imaging compositions and methods |
| 01/19/2000 | CN1241634A Phytase formulation |
| 01/19/2000 | CN1048398C Controlled release pharmaceutical preparation and method for producing the same |
| 01/19/2000 | CN1048397C Hydrogel Slow-releasing agent |
| 01/19/2000 | CN1048396C Granular preparation |
| 01/19/2000 | CN1048395C Pharmaceutical granulate |
| 01/19/2000 | CN1048393C Aqueous drug composition having property of reversible thermosetting gelation |
| 01/19/2000 | CN1048384C Growth promoting composition for fish and its using method |
| 01/18/2000 | US6015913 Heating cocoa beans to loosen shell without roasting nib, winnowing nibs from shells, screw pressing nibs to produce cocoa butter and partially defatted cocoa solids |
| 01/18/2000 | US6015897 For conjugation to ligand/antiligand pair and use in delivery of therapeutic or diagnostic agent to targeted site |